{"entity":{"id":"nct04285086","kind":"trial","name":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","aka":[],"tldr":"A phase 3 trial of Ropeginterferon alfa-2b and Anagrelide in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.","summary":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance is a phase 3 interventional study registered as NCT04285086 by PharmaEssentia, with 174 participants enrolled, started 2020-08-25 and due to reach its primary completion in 2024-11-12. Interventions recorded: Ropeginterferon alfa-2b and Anagrelide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04285086","url":"https://clinicaltrials.gov/study/NCT04285086"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":["ropeginterferon-alfa-2b","anagrelide"],"companies":["pharmaessentia"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04285086","phase":"3","setting":"A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.","sponsor":"PharmaEssentia","enrolled":174,"outcomes":[]},"route":"/trials/nct04285086/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"drug":[{"id":"anagrelide","kind":"drug","name":"Anagrelide","route":"/drugs/anagrelide/"},{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/"}],"company":[{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/"}]}}